Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 30;11(13):3799.
doi: 10.3390/jcm11133799.

Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

Vikash Jaiswal  1 , Song Peng Ang  2 , Kriti Lnu  3 , Angela Ishak  4 , Nishan Babu Pokhrel  5 , Jia Ee Chia  6 , Adrija Hajra  7 , Monodeep Biswas  8 , Andrija Matetic  9   10 , Ravinder Dhatt  3 , Mamas A Mamas  10
Affiliations
Review

Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis

Vikash Jaiswal et al. J Clin Med. .

Abstract

Various studies have suggested the possible cardiovascular (CV) protective effects of the pneumococcal vaccine (PV). Therefore, we conducted a meta-analysis to assess the association between recipients of PV with mortality and CV outcomes among patients with and without established cardiovascular disease. We performed a systematic literature search in PubMed, Embase, and Scopus for studies evaluating the effect of PV on mortality and CV outcomes. A total of 15 studies with 347,444 patients were included in the meta-analysis: 111,784 patients received PV (32%) and 235,660 patients were in the unvaccinated group (68%). Recipients of PV were associated with decreased all-cause mortality (HR, 0.76 (95% CI: 0.66 to 0.87), p < 0.001). PV was associated with a decrease in the incidence of myocardial infarction (MI) (HR, 0.73 (95% CI: 0.56−0.96), p = 0.02), without significant reduction in CV mortality (HR, 0.87 (95% CI: 0.72−1.07), p = 0.18) and stroke (HR, 1.01 (95% CI: 0.93−1.10), p = 0.82). Our study found PV was associated with decreased risk of all-cause mortality and MI. Future RCTs will be necessary to confirm benefits associated with receipt of PV.

Keywords: 23 PV vaccine; mortality; myocardial infarction; pneumococcal vaccine; stroke.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart of the search strategy for systematic review and meta-analysis.
Figure 2
Figure 2
Forest plot of primary outcome: all-cause mortality [31,32,34,35,37,38,41,42,43].
Figure 3
Figure 3
Forest plot of secondary outcomes including (A) MI, (B) CV mortality, and (C) Stroke [31,32,33,34,35,36,37,39,40,42,43,44,45].
See this image and copyright information in PMC

References

    1. World Health Organization Cardiovascular Disease (CVDs) [(accessed on 1 April 2022)]. Available online: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases...
    1. Jackson M.L., Nelson J.C., Jackson L.A. Risk factors for community-acquired pneumonia in immunocompetent seniors. J. Am. Geriatr. Soc. 2009;57:882–888. doi: 10.1111/j.1532-5415.2009.02223.x. - DOI - PubMed
    1. Watt J.P., O’Brien K.L., Benin A.L., McCoy S.I., Donaldson C.M., Reid R., Schuchat A., Zell E.R., Hochman M., Santosham M., et al. Risk factors for invasive pneumococcal disease among Navajo adults. Am. J. Epidemiol. 2007;166:1080–1087. doi: 10.1093/aje/kwm178. - DOI - PubMed
    1. Soto-Gomez N., Anzueto A., Waterer G.W., Restrepo M.I., Mortensen E.M. Pneumonia: An arrhythmogenic disease? Am. J. Med. 2013;126:43–48. doi: 10.1016/j.amjmed.2012.08.005. - DOI - PMC - PubMed
    1. Corrales-Medina V.F., Musher D.M., Shachkina S., Chirinos J.A. Acute pneumonia and the cardiovascular system. Lancet. 2013;381:496–505. doi: 10.1016/S0140-6736(12)61266-5. - DOI - PubMed

LinkOut - more resources